We were delighted to speak with Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, New York, US) around his talk on ‘Overcoming the Plateau in IBD Treatment’ which was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
- Could you tell us about the plateau in drug efficacy that occurs with current treatment options? (0:25)
- How important is the personalised paradigm in the treatment of IBD? (2:28)
- What are the unmet needs for biomarkers in the personalisation of IBD treatment and what has been achieved so far? (3:30)
- What is ‘Rational polypharmacy’ and what is the potential of combining therapies for overcoming the plateau in IBD treatment? (5:27)
- Is prevention during the pre-clinical phase of IBD the path to ‘breaking the ceiling’ in treatment? (9:50)
Disclosures: Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS). His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with […]
Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and Long Term Extension Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis. The abstract entitled ‘133: SAFETY ANALYSIS […]
Stefan Schreiber, DDW 2021: True North Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod. The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!